摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-[2-(3-methyl-3H-imidazol-4-ylamino)pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile | 1356226-41-9

中文名称
——
中文别名
——
英文名称
5-[2-(3-methyl-3H-imidazol-4-ylamino)pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile
英文别名
US8962609, Dmx-60;5-[2-[(3-methylimidazol-4-yl)amino]pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile
5-[2-(3-methyl-3H-imidazol-4-ylamino)pyrimidin-4-yl]-2-pyrrolidin-1-ylbenzonitrile化学式
CAS
1356226-41-9
化学式
C19H19N7
mdl
——
分子量
345.407
InChiKey
NYTXNSGKXJZIID-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    26
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.26
  • 拓扑面积:
    82.7
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • PYRIMIDINE COMPOUNDS AS INHIBITORS OF PROTEIN KINASES IKK EPSILON AND/OR TBK-1, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
    申请人:Perrior Trevor Robert
    公开号:US20130267491A1
    公开(公告)日:2013-10-10
    C Compounds of the general formula (I) and salts thereof are useful in the treatment of diseases associated with aberrant activity of the protein kinases IKKε and/or TBK-1: in which: R 1 represents an aliphatic heterocyclyl group having 4, 5, 6 or 7 ring atoms, bonded to the phenyl group shown in formula I through a ring nitrogen atom, and optionally substituted by one or more substituents defined in the Specification; R 2 represents a phenyl or heteroaryl group which is optionally substituted by one or more substituents defined in the Specification; and each of R 3 and R 4 independently represents a hydrogen atom or a C 1-4 alkyl group.
    通式(I)的化合物及其盐在治疗与蛋白激酶IKKε和/或TBK-1的异常活性相关的疾病方面是有用的:其中:R1代表通过一个环氮原子与通式I中所示的苯基相连的具有4、5、6或7个环原子的脂肪族杂环基,可选地被本说明书中定义的一个或多个取代基取代;R2代表一个苯基或杂环基,可选地被本说明书中定义的一个或多个取代基取代;R3和R4各自独立地代表氢原子或C1-4烷基。
  • Pyrimidine compounds as inhibitors of protein kinases IKK epsilon and/or TBK-1, processes for their preparation, and pharmaceutical compositions containing them
    申请人:Domainex Limited
    公开号:EP2595964B1
    公开(公告)日:2015-04-29
  • US8962609B2
    申请人:——
    公开号:US8962609B2
    公开(公告)日:2015-02-24
查看更多